Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia

Nature Reviews Cancer

Volumn 6, Issue 5, 2006, Pages 347-359

  Grabher, Clemens ^a   Von Boehmer, Harald ^a   Look, A Thomas ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; IMATINIB; NOTCH1 RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER MODEL; CHROMOSOME TRANSLOCATION 7; GENE; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MUTATION; HUMAN; LEUKEMOGENESIS; NONHUMAN; NOTCH1 GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; THYMOCYTE;

GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, T-CELL, ACUTE; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION;

EID: 33646366173     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1880     Document Type: Review

References (175)

1. Pui, C. H., Relling, M. V. & Downing, J. R. Acute lymphoblastic leukemia. N. Engl. J. Med. 350, 1535-1548 (2004).
2. Thomas, X. et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J. Clin. Oncol. 22, 4075-4086 (2004).
3. Annino, L. et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99, 863-871 (2002).
4. Linker, C., Damon, L., Ries, C. & Navarro, W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J. Clin. Oncol. 20, 2464-2471 (2002).
5. Hunault, M. et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 104, 3028-3037 (2004).
6. Armstrong, S. A. & Look, A. T. Molecular genetics of acute lymphoblastic leukemia. J. Clin. Oncol. 23, 6306-6315 (2005).
7. Erikson, J. et al. Deregulation of c-myc by translocation of the α-locus of the T-cell receptor in T-cell leukemias. Science 232, 884-886 (1986).
8. Meng, Y. S., Khoury, H., Dick, J. E. & Minden, M. D. Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia. Leukemia 19, 1941-1947 (2005).
9. Baer, R. TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. Semin. Cancer Biol. 4, 341-347 (1993).
10. Bain, G. et al. E2A deficiency leads to abnormalities in αβ T-cell development and to rapid development of T-cell lymphomas. Mol. Cell. Biol. 17, 4782-4791 (1997).
11. Yan, W. et al. High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol. Cell. Biol. 17, 7317-7327 (1997).
12. O'Neil, J., Billa, M., Oikemus, S. & Kelliher, M. The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice. Oncogene 20, 3897-3905 (2001).
13. Chervinsky, D. S. et al. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice. Mol. Cell. Biol. 19, 5025-5035 (1999).
14. Ferrando, A. A. et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75-87 (2002). This study represents one of the first attempts to use gene-expression profiling for the classification of T-ALL subtypes, identification of novel oncogenic factors and the prognostic relevance of gene profiles.
15. Ferrando, A. A. et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 363, 535-536 (2004).
16. Ferrando, A. A. et al. Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood 103, 1909-1911 (2004).
17. Wadman, I. et al. Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia. EMBO J. 13, 4831-4839 (1994).
18. Valge-Archer, V. E. et al. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Proc. Natl Acad. Sci. USA 91, 8617-8621 (1994).
19. Look, A. T. Oncogenic transcription factors in the human acute leukemias. Science 278, 1059-1064 (1997).
20. Speleman, F. et al. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia 19, 358-366 (2005).
21. Soulier, J. et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 106, 274-286 (2005).
22. Taghon, T. et al. HOX-A10 regulates hematopoietic lineage commitment: evidence for a monocyte-specific transcription factor. Blood 99, 1197-1204 (2002).
23. Taghon, T. et al. Homeobox gene expression profile in human hematopoietic multipotent stem cells and T-cell progenitors: implications for human T-cell development. Leukemia 17, 1157-1163 (2003).
24. Ferrando, A. A. et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 102, 262-268 (2003).
25. Roberts, C. W., Shutter, J. R. & Korsmeyer, S. J. Hox11 controls the genesis of the spleen. Nature 368, 747-749 (1994).
26. Berger, R. et al. t(5;14)/HOX11 L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Croupe Francais de Cytogenetique Hematologique (GFCH). Leukemia 17, 1851-1857 (2003).
27. Ballerini, P. et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 100, 991-997 (2002).
28. Cave, H. et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 103, 442-450 (2004).
29. Dreyling, M. H. et al. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc. Natl Acad. Sci. USA 93, 4804-4809 (1996).
30. Asnafi, V. et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRγδ lineage. Blood 102, 1000-6 (2003).
31. Wechsler, D. S. et al. A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein. Genes Chromosomes Cancer 36, 26-36 (2003).
32. Chaplin, T. et al. The t(10;11) translocation in acute myeloid leukemia (M5) consistently fuses the leucine zipper motif of AF10 onto the HRX gene. Blood 86, 2073-2076 (1995).
33. Graux, C. et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nature Genet. 36, 1084-1089 (2004).
34. De Keersmaecker, K. et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 105, 4849-4852 (2005).
35. Van Limbergen, H. et al. Molecular cytogenetic and clinical findings in ETV6-ABL1-positive leukemia. Genes Chromosomes Cancer 30, 274-282 (2001).
36. Pear, W. S. et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr-abl-transduced bone marrow. Blood 92, 3780-3792 (1998).
37. Lacronique, V. et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312 (1997).
38. Carron, C. et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95, 3891-3899 (2000).
39. Tycko, B., Smith, S. D. & Sklar, J. Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia. J. Exp. Med. 174, 867-873 (1991).
40. Wright, D. D., Sefton, B. M. & Kamps, M. P. Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol. Cell. Biol. 14, 2429-2437 (1994).
41. Lubbert, M. et al. N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood 75, 1163-1169 (1990).
42. Yokota, S. et al. Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases. Int. J. Hematol. 67, 379-387 (1998).
43. Kawamura, M. et al. Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia. Blood 85, 2546-2552 (1995).
44. Ellisen, L. W. et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649-661 (1991). Describes the identification of the first human Notch gene (NOTCH 1). It also indicates, for the first time, a causative role of activated Notch signalling in human neoplasms.
45. Morgan, T. H. The theory of the gene. Am. Nat. 51, 513-544 (1917).
46. Wharton, K. A., Johansen, K. M., Xu, T. & Artavanis-Tsakonas, S. Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing ECF-like repeats. Cell 43, 567-581 (1985).
47. Lai, E. C. Notch signaling: control of cell communication and cell fate. Development 131, 965-973 (2004).
48. Radtke, F., Wilson, A., Mancini, S. J. & MacDonald, H. R. Notch regulation of lymphocyte development and function. Nature Immunol. 5, 247-253 (2004).
49. Reizis, B. & Leder, P. Direct induction of T lymphocyte-specific gene expression by the mammalian Notch signaling pathway. Genes Dev. 16, 295-300 (2002).
50. Wolfer, A. et al. Inactivation of Notch 1 impairs VDJβ rearrangement and allows pre-TCR-independent survival of early αβ lineage thymocytes. Immunity 16, 869-879 (2002).
51. Tanigaki, K. et al. Regulation of αβ/γδ cell lineage commitment and peripheral T cell responses by Notch/RBP-J signaling. Immunity 20, 611-622 (2004).
52. Ciofani, M. et al. Obligatory role for cooperative signaling by pre-TCR and Notch during thymocyte differentiation. J. Immunol. 172, 5230-5239 (2004).
53. Radtke, R et al. Deficient T cell fate specification in mice with an induced inactivation of Notch 1. Immunity 10, 547-558 (1999). Documents the requirement for Notch 1 activity in T-cell development. A lack of Notch 1 function results in B-cell specification at the expense of T-cells.
54. Wilson, A., MacDonald, H. R. & Radtke, F. Notch 1-deficient common lymphoid precursors adopt a B cell fate in the thymus. J. Exp. Med. 194, 1003-1012 (2001).
55. Nicolas, M. et al. Notch 1 functions as a tumor suppressor in mouse skin. Nature Genet. 33, 416-421 (2003).
56. Gallahan, D. & Callahan, R. Mammary tumorigenesis in feral mice: identification of a new int locus in mouse mammary tumor virus (Czech II)-induced mammary tumors. J. Virol. 61, 66 (1987).
57. Weijzen, S. et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nature Med. 8, 979-986 (2002). Shows that the sustained presence of activated Notch 1 signalling is required for the manifestation of neoplastic properties in culture.
58. Zagouras, P. et al. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc. Natl. Acad. Sci. USA 92, 6414-6418 (1995).
59. Fre, S. et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature 435, 964-968 (2005).
60. van Es, J. H. et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959-963 (2005).
61. Joutel, A. et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383, 707-710 (1996).
62. Li, L. et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch 1. Nature Genet. 16, 243-251 (1997).
63. Oda, T. et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nature Genet. 16, 235-242 (1997).
64. Taghon, T. et al. Developmental and molecular characterization of emerging β- and γδ-selected pre-T cells in the adult mouse thymus. Immunity 24, 53-64 (2006).
65. Sambandam, A. et al. Notch signaling controls the generation and differentiation of early T lineage progenitors. Nature Immunol. 6, 663-670 (2005).
66. Berghmans, S. et al. Making waves in cancer research: new models in the zebrafish. Biotechniques 39, 227-237 (2005).
67. Lehar, S. M., Dooley, J., Farr, A. G. & Bevan, M. J. Notch ligands Delta1 and Jagged1 transmit distinct signals to T-cell precursors. Blood 105, 1440-1447 (2005).
68. Man, H. et al. Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int. Immunol. 14, 637-645 (2002).
69. Izon, D. J. et al. Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch 1. Immunity 16, 231-243 (2002).
70. Maillard, I. et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood 104, 1696-1702 (2004).
71. Radtke, F. et al. Notch 1 deficiency dissociates the intrathymic development of dendritic cells and T cells. J. Exp. Med. 191, 1085-1094 (2000).
72. Pui, J. C. et al. Notch 1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 11, 299-308 (1999).
73. Jaleco, A. C. et al. Differential effects of Notch ligands Delta-1 and Jagged-1 in human lymphoid differentiation. J. Exp. Med. 194, 991-1002 (2001).
74. Schmitt, T. M. & Zuniga-Pflucker, J. C. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 17, 749-756 (2002).
75. Jiang, R. et al. Defects in limb, craniofacial, and thymic development in Jagged2 mutant mice. Genes Dev. 12, 1046-1057 (1998).
76. Washburn, T. et al. Notch activity influences the αβ versus γδ cell lineage decision. Cell 88, 833-843 (1997).
77. + cell-dependent mechanism. J. Clin. Invest. 112, 1741-1750 (2003).
78. Yvon, E. S. et al. Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood 102, 3815-3821 (2003).
79. Adler, S. H. et al. Notch signaling augments T cell responsiveness by enhancing CD25 expression. J. Immunol. 171, 2896-2903 (2003).
80. + T cells. Int. Immunol. 12, 177-185 (2000).
81. Palaga, T., Miele, L., Golde, T. E. & Osborne, B. A. TCR-mediated notch signaling regulates proliferation and IFN-γ production in peripheral T cells. J. Immunol. 171, 3019-3024 (2003).
82. Hadland, B. K. et al. A requirement for Notch1 distinguishes 2 phases of definitive hematopoiesis during development. Blood 104, 3097-3105 (2004).
83. Kumano, K. et al. Notch1 but not Notch2 is essential for generating hematopoietic stem cells from endothelial cells. Immunity 18, 699-711 (2003).
84. Varnum-Finney, B. et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nature Med. 6, 1278-1281 (2000).
85. Varnum-Finney, B., Brashem-Stein, C. & Bernstein, I. D. Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability. Blood 101, 1784-1789 (2003).
86. Stier, S. et al. Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood 99, 2369-2378 (2002).
87. Duncan, A. W. et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nature Immunol. 6, 314-322 (2005).
88. Wettstein, D. A., Turner, D. L. & Kintner, C. The Xenopus homolog of Drosophila Suppressor of Hairless mediates Notch signaling during primary neurogenesis. Development 124, 693-702 (1997).
89. Hsieh, J. J. & Hayward, S. D. Masking of the CBF1/RBPJ κ transcriptional repression domain by Epstein-Barr virus EBNA2. Science 268, 560-563 (1995).
90. Aster, J. et al. Functional analysis of the TAN-1 gene, a human homolog of Drosophila notch. Cold Spring Harb. Symp. Quant. Biol. 59, 125-136 (1994).
91. Pear, W. S. et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med. 183, 2283-2291 (1996). This is the first documentation of the oncogenic potential of human TAN1 in the haematopoietic system of a murine model.
92. Aster, J. C. et al. Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol. Cell. Biol. 20, 7505-7515 (2000).
93. Allman, D. et al. Separation of Notch1 promoted lineage commitment and expansion/transformation in developing T cells. J. Exp. Med. 194, 99-106 (2001).
94. Robey, E. et al. An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell 87, 483-492 (1996).
95. Fowlkes, B. J. & Robey, E. A. A reassessment of the effect of activated Notch1 on CD4 and CD8 T cell development. J. Immunol. 169, 1817-1821 (2002).
96. Tsuji, H. et al. Radiation-induced deletions in the 5′ end region of Notch1 lead to the formation of truncated proteins and are involved in the development of mouse thymic lymphomas. Carcinogenesis 24, 1257-1268 (2003).
97. O'Neil, J. et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 107, 781-785 (2005).
98. Lin, Y. W., Nichols, R. A., Letterio, J. J. & Aplan, P. D. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 107, 2540-2543 (2005).
99. Ma, S. K., Wan, T. S. & Chan, L. C. Cytogenetics and molecular genetics of childhood leukemia. Hematol. Oncol. 17, 91-105 (1999).
100. Jundt, F. et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 99, 3398-3403 (2002).
101. Bellavia, D. et al. Combined expression of pTα and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc. Natl Acad. Sci. USA 99, 3788-3793 (2002).
102. Chiaramonte, R. et al. Differential regulation of Notch signal transduction in leukaemia and lymphoma cells in culture. J. Cell Biochem. 88, 569-577 (2003).
103. Weng, A. P. et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol. Cell. Biol. 23, 655-664 (2003).
104. Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004). Demonstrates the causative role of somatic activating mutations in NOTCH1 in the development of human T-ALL.
105. Sanchez-Irizarry, C. et al. Notch subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, respectively, on a novel domain and the LNR repeats. Mol. Cell. Biol. 24, 9265-9273 (2004).
106. Greenwald, I. LIN-12/Notch signaling: lessons from worms and flies. Genes Dev. 12, 1751-1162 (1998).
107. Berry, L. W., Westlund, B. & Schedl, T. Germ-line tumor formation caused by activation of glp-1, a Caenorhabditis elegans member of the Notch family of receptors. Development 124, 925-936 (1997).
108. Gupta-Rossi, N. et al. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J. Biol. Chem. 276, 34371-34378 (2001).
109. Feldman, B. J., Hampton, T. & Cleary, M. L. A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice. Blood 96, 1906-1913 (2000).
110. Hoemann, C. D. et al. Two distinct Notch1 mutant alleles are involved in the induction of T-cell leukemia in c-myc transgenic mice. Mol. Cell. Biol. 20, 3831-3842 (2000).
111. Deftos, M. L. et al. Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. Immunity 13, 73-84 (2000).
112. Sade, H., Krishna, S. & Sarin, A. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J. Biol. Chem. 279, 2937-2944 (2004).
113. Sicinska, E. et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4, 451-461 (2003).
114. Engel, I. & Murre, C. E2A proteins enforce a proliferation checkpoint in developing thymocytes. EMBO J. 23, 202-211 (2004).
115. Nie, L., Xu, M., Vladimirova, A. & Sun, X. H. Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J. 22, 5780-5792 (2003).
116. Engel, I. & Murre, C. Disruption of pre-TCR expression accelerates lymphomagenesis in E2A-deficient mice. Proc. Natl Acad. Sci. USA 99, 11322-11327 (2002).
117. Talora, C. Pre-TCR-triggered ERK signalling-dependent down regulation of E2A activity. EMBO Rep. 4, 1067-1072 (2003).
118. Ordentlich, P. et al. Notch inhibition of E47 supports the existence of a novel signaling pathway. Mol. Cell. Biol. 18, 2230-2239 (1998).
119. Reschly, E. J. et al. Notch1 promotes survival of E2A-deficient T cell lymphomas through Pre-T cell receptor dependent and independent mechanisms. Blood 31 Jan 2006 (doi:10.1182/blood-2005-09-3551).
120. Beverly, L. J., Felsher, D. W. & Capobianco, A. J. Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Res. 65, 7159-7168 (2005).
121. Jehn, B. M., Bielke, W., Pear, W. S. & Osborne, B. A. Cutting edge: protective effects of notch-1 on TCR-induced apoptosis. J. Immunol. 162, 635-638 (1999).
122. Deftos, M. L., He, Y. W., Ojala, E. W. & Bevan, M. J. Correlating notch signaling with thymocyte maturation. Immunity 9, 777-786 (1998).
123. He, Y. W. Orphan nuclear receptors in T lymphocyte development. J. Leukoc. Biol. 72, 440-446 (2002).
124. Girard, L. et al. Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis. Genes Dev. 10, 1930-1944 (1996).
125. Beverly, L. J. & Capobianco, A. J. Perturbation of Ikaros isoform selection by MLV integration is a cooperative event in Notch(IC)-induced T cell leukemogenesis. Cancer Cell 3, 551-564 (2003).
126. Dumortier, A. et al. Notch activation is an early and critical event during t-cell leukemogenesis in Ikaros-deficient mice. Mol. Cell. Biol. 26, 209-220 (2006).
127. Dupuy, A. J. et al. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436, 221-226 (2005).
128. Yeoh, E. J. et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133-143 (2002).
129. Garces, C. et al. Notch-1 controls the expression of fatty acid-activated transcription factors and is required for adipogenesis. J. Biol. Chem. 272, 29729-29734 (1997).
130. Petit, A. et al. New protease inhibitors prevent γ-secretase-mediated production of αβ40/42 without affecting Notch cleavage. Nature Cell Biol. 3, 507-511 (2001).
131. Fortini, M. E. γ-Secretase-mediated proteolysis in cell-surface-receptor signalling. Nature Rev. Mol. Cell Biol. 3, 673-84 (2002).
132. Wong, G. T. et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876-12882 (2004). The first report that documents the long-term effects of oral administration of GSIs in mice. The authors provide evidence that significant side effects are due to inhibition of Notch signalling, including arrest of T-cell development and aberrant differentiation of gut epithelium.
133. Minter, L. M. et al. Inhibitors of γ-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nature Immunol. 6, 680-688 (2005).
134. O'Neil, J. et al. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5, 587-596 (2004).
135. Feldman, B. J., Hampton, T. & Cleary, M. L. A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice. Blood 96, 1906-1913 (2000).
136. Mikkers, H. & Berns, A. Retroviral insertional mutagenesis: tagging cancer pathways. Adv. Cancer Res. 88, 53-99 (2003).
137. Collier, L. S. et al. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436, 272-276 (2005).
138. Langenau, D. M. et al. Myc-induced T cell leukemia in transgenic zebrafish. Science 299, 887-890 (2003).
139. Langenau, D. M. et al. In vivo tracking of T cell development, ablation, and engraftment in transgenic zebrafish. Proc. Natl Acad. Sci. USA 101, 7369-7374 (2004).
140. Langenau, D. M. et al. Crellox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 102, 6068-6073 (2005).
141. Okajima, T., Xu, A., Lei, L. & Irvine, K. D. Chaperone activity of protein O-fucosyltransferase 1 promotes notch receptor folding. Science 307, 1599-1603 (2005).
142. Selkoe, D. & Kopan, R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci. 26, 565-597 (2003).
143. Shah, S. et al. Nicastrin functions as a γ-secretase-substrate receptor. Cell 122, 435-447 (2005).
144. Nam, Y., Weng, A. P., Aster, J. C. & Blacklow, S. C. Structural requirements for assembly of the CSL-intracellular Notch1-Mastermind-like 1 transcriptional activation complex. J. Biol. Chem. 278, 21232-21239 (2003).
145. Lubman, O. Y., Korolev, S. V. & Kopan, R. Anchoring notch genetics and biochemistry; structural analysis of the ankyrin domain sheds light on existing data. Mol. Cell 13, 619-626 (2004).
146. Fryer, C. J. et al. Mastermind mediates chromatin-specific transcription and turnover of the Notch enhancer complex. Genes Dev. 16, 1397-1411 (2002).
147. Wallberg, A. E., Pedersen, K., Lendahl, U. & Roeder, R. G. p300 and PCAF act cooperatively to mediate transcriptional activation from chromatin templates by notch intracellular domains in vitro. Mol. Cell. Biol. 22, 7812-7819 (2002).
148. Jeffries, S., Robbins, D. J. & Capobianco, A. J. Characterization of a high-molecular-weight Notch complex in the nucleus of Notch(ic)-transformed RKE cells and in a human T-cell leukemia cell line. Mol. Cell. Biol. 11, 3927-3941 (2002).
149. Berdnik, D., Torok, T., Gonzalez-Gaitan, M. & Knoblich, J. A. The endocytic protein α-Adaptin is required for numb-mediated asymmetric cell division in Drosophila. Dev. Cell 3, 221-231 (2002).
150. McGill, M. A. & McGlade, C. J. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J. Biol. Chem. 278, 23196-23203 (2003).
151. Matsuno, K. et al. Deltex acts as a positive regulator of Notch signaling through interactions with the Notch ankyrin repeats. Development 121, 2633-2644 (1995).
152. Lai, E. C. Protein degradation: four E3s for the notch pathway. Curr. Biol. 12, R74-R78 (2002).
153. Fryer, C. J., White, J. B. & Jones, K. A. Mastermind recruits CycC-CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol. Cell 16, 509-520 (2004).
154. Lu, M., Gong, Z. Y., Shen, W. F. & Ho, A. D. The tcl-3 proto-oncogene altered by chromosomal translocation in T-cell leukemia codes for a homeobox protein. EMBO J. 10, 2905-2910 (1991).
155. Hatano, M. et al. Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science 253, 79-82 (1991).
156. Kennedy, M. A. et al. HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24. Proc. Natl Acad. Sci. USA 88, 8900-8904 (1991).
157. Dube, I. D. et al. A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). Blood 78, 2996-3003 (1991).
158. Hansen-Hagge, T. E. et al. Disruption of the RanBP17/Hox11L2 region by recombination with the TCRδ locus in acute lymphoblastic leukemias with t(5;14)(q34;q11). Leukemia 16, 2205-2212 (2002).
159. Wang, J. et al. The t(14;21)(q11.2;q22) chromosomal translocation associated with T-cell acute lymphoblastic leukemia activates the BHLHB1 gene. Proc. Natl Acad. Sci. USA 97, 3497-3502 (2000).
160. Mellentin, J. D., Smith, S. D. & Cleary, M. L. lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 58, 77-83 (1989).
161. Begley, C. G. et al. Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor δ-chain diversity region and results in a previously unreported fusion transcript. Proc. Natl Acad. Sci. USA 86, 2031-2035 (1989).
162. Chen, Q. et al. The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J. 9, 415-424 (1990).
163. Xia, Y. et al. TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia. Proc. Natl Acad. Sci. USA 88, 11416-11420 (1991).
164. Finger, L. R. et al. A common mechanism of chromosomal translocation in T- and B-cell neoplasia. Science 234, 982-985 (1986).
165. McKeithan, T. W. et al. Molecular cloning of the breakpoint junction of a human chromosomal 8;14 translocation involving the T-cell receptor α-chain gene and sequences on the 3′ side of MYC. Proc. Natl Acad. Sci. USA 83, 6636-6640 (1986).
166. Shima, E. A. et al. Gene encoding the α chain of the T-cell receptor is moved immediately downstream of c-myc in a chromosomal 8;14 translocation in a cell line from a human T-cell leukemia. Proc. Natl Acad. Sci. USA 83, 3439-3443 (1986).
167. Greenberg, J. M. et al. Segmental and developmental regulation of a presumptive T-cell oncogene in the central nervous system. Nature 344, 158-160 (1990).
168. McGuire, E. A. et al. The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-1, a gene encoding a potential zinc finger protein. Mol. Cell. Biol. 9, 2124-2132 (1989).
169. Boehm, T. et al. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc. Natl Acad. Sci. USA 88, 4367-4371 (1991).
170. Royer-Pokora, B., Loos, U. & Ludwig, W. D. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 6, 1887-1893 (1991).
171. Hussey, D. J. et al. The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia. Blood 94, 2072-2079 (1999).
172. Carlson, K. M. et al. Identification and molecular characterization of CALM-AF10 fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia. Leukemia 14, 100-104 (2000).
173. Ferrando, A. A. & Look, A. T. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin. Hematol. 37, 381-395 (2000).
174. Zweidler-McKay, P. A. & Pear, W. S. Notch and T cell malignancy. Semin. Cancer Biol. 14, 329-340 (2004).
175. Aster, J. C. & Pear, W. S. Notch signaling in leukemia. Curr. Opin. Hematol. 8, 237-244 (2001).